Biodesix Ownership

BDSX Stock  USD 1.40  0.01  0.71%   
Biodesix holds a total of 145.47 Million outstanding shares. Biodesix retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2017-12-31
Previous Quarter
127.2 M
Current Value
146.3 M
Avarage Shares Outstanding
50.4 M
Quarterly Volatility
33.6 M
 
Covid
Some institutional investors establish a significant position in stocks such as Biodesix in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Biodesix, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividends Paid is likely to drop to about 534 K in 2024. Dividend Paid And Capex Coverage Ratio is likely to drop to -1.04 in 2024. Common Stock Shares Outstanding is likely to rise to about 86.2 M in 2024, whereas Net Loss is likely to drop (61.8 M) in 2024.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodesix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more information on how to buy Biodesix Stock please use our How to Invest in Biodesix guide.

Biodesix Stock Ownership Analysis

About 47.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.37. Biodesix had not issued any dividends in recent years. Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado. Biodesix operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 218 people. For more info on Biodesix please contact Scott Hutton at 303 417 0500 or go to https://www.biodesix.com.
Besides selling stocks to institutional investors, Biodesix also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Biodesix's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Biodesix's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Biodesix Quarterly Liabilities And Stockholders Equity

102.74 Million

About 47.0% of Biodesix are currently held by insiders. Unlike Biodesix's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Biodesix's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Biodesix's insider trades

Biodesix Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biodesix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biodesix backward and forwards among themselves. Biodesix's institutional investor refers to the entity that pools money to purchase Biodesix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Lmr Partners Llp2024-06-30
1.6 M
Essex Investment Management Company, Llc2024-09-30
971.2 K
Wells Fargo & Co2024-06-30
931.2 K
Amh Equity Ltd2024-09-30
696.1 K
Geode Capital Management, Llc2024-06-30
533.9 K
Blackrock Inc2024-06-30
415.9 K
Perkins Capital Management Inc2024-06-30
414.8 K
Legato Capital Management Llc2024-06-30
334.3 K
State Street Corp2024-06-30
288.6 K
Telemark Asset Management, Llc2024-06-30
8.3 M
Soleus Capital Management, L.p.2024-06-30
6.1 M
Note, although Biodesix's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biodesix Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biodesix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biodesix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biodesix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Biodesix Stock Analysis

When running Biodesix's price analysis, check to measure Biodesix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodesix is operating at the current time. Most of Biodesix's value examination focuses on studying past and present price action to predict the probability of Biodesix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodesix's price. Additionally, you may evaluate how the addition of Biodesix to your portfolios can decrease your overall portfolio volatility.